SCHEMBL13651772

SCHEMBL13651772

CCCCCCOc1ccc(C2OCC2(C)C)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.50
▸ NR5A1 Q13285 1/20 0.47
▸ NPC1 O15118 2/20 0.45
▸ LTA4H P09960 3/20 0.44
▸ TP53 P04637 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MAOA P21397 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43
▸ PLA2G4B P0C869 1/20 0.42
▸ MMP2 P08253 1/20 0.42
▸ MMP3 P08254 1/20 0.42
▸ MMP9 P14780 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13651773 1.00 LMNA (0.50) LMNANR5A1NPC1LTA4HTP53
SCHEMBL14193797 0.99 LMNA (0.51) LMNANR5A1NPC1LTA4HTP53
SCHEMBL4806456 0.96 NPC1 (0.48) LMNANR5A1NPC1LTA4HMAPT
SCHEMBL13651779 0.90 ALDH1A1 (0.49) LMNANPC1LTA4HGAAMAPT
SCHEMBL13651775 0.89 CRBN (0.44) LMNANPC1GAAMAPTRAB9A
SCHEMBL13651823 0.88 MAPT (0.39) LMNANPC1MAPTMAOAMAOB
SCHEMBL14193812 0.87 LMNA (0.39) LMNANPC1MAPTMAOAMAOB
SCHEMBL12835195 0.86 LMNA (0.38) LMNANR5A1NPC1TP53GAA
SCHEMBL14193811 0.84 CRBN (0.39) LMNANPC1GAAMAPTRAB9A
SCHEMBL14193810 0.84 NPC1 (0.37) LMNANPC1MAPTRAB9AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090252895-A1 Actinic ray curable composition, actinic ray curable ink and image formation method employing the ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-10-08 — — US disclosed
US-20090252895-A1 Actinic ray curable composition, actinic ray curable ink and image formation method employing the ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-10-08 — — US disclosed
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-05-08 — — US disclosed
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-05-08 — — US disclosed
US-7360883-B2 Active ray curable ink, image forming method and ink-jet recording apparatus KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-04-22 — — US disclosed
US-7360883-B2 Active ray curable ink, image forming method and ink-jet recording apparatus KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-04-22 — — US disclosed
EP-1840148-A1 POLYMERIZABLE ACTINIC RADIATION CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTINIC RADIATION CURABLE INK AND IMAGE FORMATION METHOD, AND INK JET RECORDING APPARATUS AND EPOXY COMPOUND Konica Minolta Medical & Graphic, Inc. (JP) 2007-10-03 — — EP disclosed
US-20070219292-A1 INK SET FOR INK-JET RECORDING, POLYMERIZATION METHOD AND IMAGE FORMING METHOD KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-09-20 — — US disclosed
US-20070219292-A1 INK SET FOR INK-JET RECORDING, POLYMERIZATION METHOD AND IMAGE FORMING METHOD KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-09-20 — — US disclosed
EP-1829936-A1 ACTIVE RAY-CURABLE COMPOSITION, ACTIVE RAY-CURABLE INK AND IMAGE-FORMING METHOD Konica Minolta Medical & Graphic, Inc. (JP) 2007-09-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound CBR3, CBR1, CNR1 LMNA 4736/4885NR5A1 4107/4885NPC1 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback